ObsEva Names Ernest Loumaye As Interim Chairman Following Resignation Of Annette Clancy; Appoints Fabien de Ladonchamps As CEO

3/13/23 7:14:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OBSV alert in real time by email

It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. The Company's Interim Chief Executive Officer, Will Brown, will serve in that position until Mr. Ladonchamps' effective date of service on May 1, 2023.

Get the next $OBSV alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OBSV

Date	Price Target	Rating	Analyst
8/30/2022		Buy → Neutral	H.C. Wainwright
6/3/2022	$6.00	Overweight	Cantor Fitzgerald
4/26/2022	$12.00	Buy	Canaccord Genuity
3/28/2022	$12.00	Buy	Aegis Capital
11/29/2021	$17.00 → $15.00	Buy	HC Wainwright & Co.

More analyst ratings

$OBSV
Press Releases

Fastest customizable press release news feed in the world

ObsEva Files Year End 2022 Financial Statements
ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing and commercializing novel therapies to improve women's health, today published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022. The U.S. Annual Report on Form 10-K can be accessed in the financial section of the Company's website, here or directly via the link here. ObsEva expects to publish its Swiss Annual Report to Shareholders, including the financial results for year end 20
3/31/23 4:01:00 PM ET
$OBSV
Biotechnology: Pharmaceutical Preparations
Health Care
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasd
3/15/23 7:00:00 AM ET
$OBSV
Biotechnology: Pharmaceutical Preparations
Health Care
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief
3/13/23 7:00:00 AM ET
$OBSV
Biotechnology: Pharmaceutical Preparations
Health Care

$OBSV
Financials

Live finance-specific insights

ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial- -Linzagolix franchise: Announced licensing agreement with Theramex to support commercialization in Europe, in addition to relationship with Syneos Health to support commercialization in the United States- Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 17, 2022 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharma
5/17/22 7:00:00 AM ET
$OBSV
$OGN
Biotechnology: Pharmaceutical Preparations
Health Care
ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
GENEVA, Switzerland – May 12, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it plans to host a conference call on Tuesday, May 17, 2022, at 8:00 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update. Individuals may participate via telephone by dialling (877) 300-8521 (domestic) or +1 (412) 317-6026 (international) and using conference ID 10166576. The webcast can be accessed live here and will also be accessible under "Events Calendar" in the investors section of ObsEva's website. The webcast will be archived on the company
5/12/22 7:00:00 AM ET
$OBSV
Biotechnology: Pharmaceutical Preparations
Health Care
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months- -Once daily linzagolix 75 mg without ABT demonstrated statistically significant improvement for dysmenorrhea versus placebo and showed improvement but did not meet the co-primary objective of reduction in non-menstrual pelvic pain at 3 months; also showed improvement in sec
1/6/22 7:00:00 AM ET
$OBSV
Biotechnology: Pharmaceutical Preparations
Health Care

$OBSV
Leadership Updates

Live Leadership Updates

ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief
3/13/23 7:00:00 AM ET
$OBSV
Biotechnology: Pharmaceutical Preparations
Health Care
ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company's Annual General Meeting on May 18, 2022. Ms. Clancy has served as a member of ObsEva's Board of Directors since 2013 and was previously Chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decided to step down from the role of Chair and retire from the Board of Directors, effective following the conclusion of the Annual General Meeting. "We could not be more pleased, or fortunate, to have
5/19/22 7:05:00 AM ET
$OBSV
Biotechnology: Pharmaceutical Preparations
Health Care
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company's Executive Committee, effective May 9, 2022. Dr. Howard, who brings to ObsEva more than 20 years of women's health expertise, will be responsible for the Company's clinical development and medical affairs strategy. She succeeds Dr. Elizabeth Garner, who will be departing the Company on May 6, 2022 to pursue a new opportunity. To help ensure a smooth tra
5/2/22 7:00:00 AM ET
$EVFM
$OBSV
$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care

ObsEva Announced Its Shares Will Be Delisted From The Nasdaq Stock Market effective March 23, 2023
ObsEva SA (NASDAQ:OBSV, SIX: OBSN)))) today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasdaq.
3/15/23 7:05:44 AM ET
$OBSV
Biotechnology: Pharmaceutical Preparations
Health Care
ObsEva Will Delist From Nasdaq Effective March 23; To Maintain SIX Swiss Exchange Listing
ObsEva SA (NASDAQ:OBSV, SIX: OBSN))))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasdaq. As previously announced, the Company received a notification letter on September 12, 2022 from Nasdaq ad
3/15/23 3:40:43 AM ET
$OBSV
Biotechnology: Pharmaceutical Preparations
Health Care
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
Gainers Provention Bio, Inc. (NASDAQ:PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. Tenax Therapeutics, Inc. (NASDAQ:TENX) rose 35.8% to $0.7737 in pre-market trading after gaining 23% on Friday. TRxADE HEALTH, Inc. (NASDAQ:MEDS) rose 15.9% to $0.40 in pre-market trading after dropping more than 5% on Friday. Meten Holding Group Ltd. (NASDAQ:METX) shares rose 15.5% to $0.2620 in pre-market trading. Myomo, Inc. (NYSE:MYO) rose 14.4% to $0.8471 in pre-market trading. Myomo is expected to report financial results for the three months and year ended Dec.
3/13/23 8:19:29 AM ET
$ACAD
$CING
$CYTO
$CZOO
Biotechnology: Pharmaceutical Preparations
Health Care
Retail-Auto Dealers and Gas Stations
Consumer Discretionary

ObsEva Names Ernest Loumaye As Interim Chairman Following Resignation Of Annette Clancy; Appoints Fabien de Ladonchamps As CEO

Chat with this insight

Recent Analyst Ratings for $OBSV

$OBSV Press Releases

Fastest customizable press release news feed in the world

ObsEva Files Year End 2022 Financial Statements

ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

$OBSV Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by ObsEva SA

SEC Form SC 13G/A filed by ObsEva SA (Amendment)

SEC Form SC 13D/A filed

$OBSV Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ObsEva downgraded by H.C. Wainwright

Cantor Fitzgerald initiated coverage on ObsEva with a new price target

Canaccord Genuity initiated coverage on ObsEva with a new price target

$OBSV Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Loumaye Ernest

SEC Form 4: Loumaye Ernest bought $440,000 worth of shares (4,000,000 units at $0.11), increasing direct ownership by 200% to 6,000,000 units

SEC Form 4 filed by Brown William Michael

$OBSV Financials

Live finance-specific insights

ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

$OBSV Leadership Updates

Live Leadership Updates

ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors

ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer

$OBSV Market Insights

Live Market Insights

$OBSV SEC Filings

ObsEva Announced Its Shares Will Be Delisted From The Nasdaq Stock Market effective March 23, 2023

ObsEva Will Delist From Nasdaq Effective March 23; To Maintain SIX Swiss Exchange Listing

Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket

SEC Form 15-12G filed by ObsEva SA

ObsEva SA filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

SEC Form 10-K filed by ObsEva SA

Recent Analyst Ratings for
$OBSV

$OBSV
Press Releases

$OBSV
Large Ownership Changes

$OBSV
Analyst Ratings

$OBSV
Insider Trading

$OBSV
Financials

$OBSV
Leadership Updates

$OBSV
Market Insights

$OBSV
SEC Filings